Currently, selective and bioavailable inhibitors of PERK (Axten et al., 2012; Moreno et al., 2013) and PKR (Couturier et al., 2010, 2012) are developed for neurodegenerative disease therapy, although their potential adverse effects (e.g., hyperglycemia with PERK inhibitors) need to be carefully addressed. The gene discussed is EIF2AK2; the disease is Hyperglycemia.